The Invisible Pandemic of Chronic Pain — And Why Medicine Has Given Up on 1.5 Billion People

1.5 billion people worldwide live with chronic pain. Most are undertreated or untreated. Here is the systemic failure behind this invisible epidemic and what a better system would look like.

Chronic pain — pain that persists beyond the normal healing time, typically defined as more than three months — affects approximately 1.5 billion people globally, making it the world's most prevalent medical condition by population affected. Its economic burden, measured in lost productivity and healthcare costs, is estimated at over $560 billion annually in the United States alone. Its burden in human suffering — years lived with disability, relationships damaged, identities lost — is incalculable.

The specific ways in which medicine has failed chronic pain patients are structural rather than merely individual. Pain as a research priority has received dramatically less funding per patient affected than comparable disease categories. The training that medical students and residents receive in pain management is inadequate — many complete their training without meaningful instruction in pain mechanisms, multimodal pain management, or the specific psychological approaches that complement pharmacological treatment.

The opioid crisis produced a specific, underappreciated second crisis: in responding to overprescribing, healthcare systems and regulators introduced barriers to opioid prescribing that have resulted in undertreated pain for patients with legitimate chronic pain conditions. Patients who were previously stable on opioid therapy have been tapered off against their clinical benefit; new chronic pain patients find opioid treatment difficult to access even when clinically appropriate.

The multimodal pain management approach — combining appropriate pharmacological treatment with physiotherapy, psychological therapy (specifically pain-focused CBT and Acceptance and Commitment Therapy), interventional procedures when indicated, and lifestyle interventions — has the strongest evidence base for achieving functional improvement in chronic pain. It requires coordinated, multidisciplinary teams that are expensive to maintain and available to only a fraction of the chronic pain patient population globally.

For the new pharmacological options: suzetrigine's approval for acute pain is the leading edge of a new class that may expand to chronic pain indications. The CGRP-targeting migraine drugs (aimovig, ajovy, emgality) represent an approach — targeting specific pain mediators rather than general pain pathways — that is producing meaningful relief in a previously treatment-resistant condition. The direction of pain pharmacology is toward specificity rather than generality, which is both the most promising scientific direction and the most expensive commercial one.